In Vitro Activity of Quinupristin/Dalfopristin and Newer Quinolones Combined with Gentamicin against Resistant Isolates of Enterococcus faecalis and Enterococcus faecium

1998 ◽  
Vol 17 (9) ◽  
pp. 657-661
Author(s):  
E. J. Giamarellos-Bourboulis ◽  
H. Sambatakou ◽  
P. Grecka ◽  
H. Giamarellou
2000 ◽  
Vol 44 (5) ◽  
pp. 1370-1374 ◽  
Author(s):  
Michael L. Zeckel ◽  
David A. Preston ◽  
Bradley S. Allen

ABSTRACT The in vitro activity of LY333328 was evaluated for 1,479 nosocomial gram-positive pathogens isolated in 12 countries during 1997. LY333328 MICs at which 90% of the isolates tested were inhibited for Enterococcus faecalis (n = 351),Enterococcus faecium (n = 100),Staphylococcus aureus (n = 593), coagulase-negative Staphylococcus species (n = 325), and Streptococcus pneumoniae(n = 110) were 1, 1, 2, 2, and 0.015 μg/ml, respectively. LY333328 demonstrated potent activity against isolates of vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and penicillin-resistant pneumococci.


2005 ◽  
Vol 96 (1) ◽  
pp. 33-36 ◽  
Author(s):  
Oliver Hendricks ◽  
Annamaria Molnar ◽  
Trine Sorensen Butterworth ◽  
Patrick Butaye ◽  
Hans Jorn Kolmos ◽  
...  

2007 ◽  
Vol 51 (6) ◽  
pp. 2043-2047 ◽  
Author(s):  
Cesar A. Arias ◽  
Kavindra V. Singh ◽  
Diana Panesso ◽  
Barbara E. Murray

ABSTRACT Ceftobiprole (BAL9141) is an investigational cephalosporin with broad in vitro activity against gram-positive cocci, including enterococci. Ceftobiprole MICs were determined for 93 isolates of Enterococcus faecalis (including 16 β-lactamase [Bla] producers and 17 vancomycin-resistant isolates) by an agar dilution method following the Clinical and Laboratory Standards Institute recommendations. Ceftobiprole MICs were also determined with a high inoculum concentration (107 CFU/ml) for a subset of five Bla producers belonging to different previously characterized clones by a broth dilution method. Time-kill and synergism studies (with either streptomycin or gentamicin) were performed with two β-lactamase-producing isolates (TX0630 and TX5070) and two vancomycin-resistant isolates (TX2484 [VanB] and TX2784 [VanA]). The MICs of ceftobiprole for 50 and 90% of the isolates tested were 0.25 and 1 μg/ml, respectively. All Bla producers and vancomycin-resistant isolates were inhibited by concentrations of ≤1 and ≤4 μg/ml, respectively, at the standard inoculum concentration. Ceftobiprole MICs at a high inoculum concentration for a subset of five Bla+ E. faecalis isolates were ≤1 μg/ml. Bactericidal activity was observed against four isolates tested at concentrations as low as 1 μg/ml regardless of the production of β-lactamase or vancomycin resistance. A combination of ceftobiprole (0.5 μg/ml) and streptomycin (25 μg/ml) was synergistic against Bla+ TX0630 and TX5070. Ceftobiprole (0.5 μg/ml) plus gentamicin (10 μg/ml) was synergistic against VanB isolate TX2484 and showed enhanced killing, but not synergism, against TX2784 (VanA), despite the absence of high-level resistance to gentamicin. In conclusion, ceftobiprole exhibited good in vitro activity against E. faecalis, including Bla+ and vancomycin-resistant strains, and exhibited synergism with aminoglycosides against selected isolates.


2014 ◽  
Vol 45 (3) ◽  
pp. 769-779 ◽  
Author(s):  
Adriana Lígia de Castilho ◽  
Juliana Paola Correa da Silva ◽  
Cintia Helena Coury Saraceni ◽  
Ingrit Elida Collantes Díaz ◽  
Mateus Luís Barradas Paciencia ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document